BioArctic AB (publ) (BRCTF)
USD 15.67
(0.0%)
USD 15.67
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 89.62 Million SEK | -44.64% |
| 2022 | 161.9 Million SEK | 50.0% |
| 2021 | 107.93 Million SEK | 14.31% |
| 2020 | 94.42 Million SEK | -3.91% |
| 2019 | 98.26 Million SEK | 18.69% |
| 2018 | 82.78 Million SEK | 54.11% |
| 2017 | 53.71 Million SEK | 19.98% |
| 2016 | 44.77 Million SEK | 20.12% |
| 2015 | 37.27 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 120.46 Million SEK | 20.27% |
| 2024 Q1 | 100.5 Million SEK | 252.68% |
| 2023 Q3 | 62.36 Million SEK | -29.17% |
| 2023 Q4 | 28.49 Million SEK | -54.3% |
| 2023 Q2 | 88.04 Million SEK | 40.42% |
| 2023 Q1 | 62.7 Million SEK | 60.35% |
| 2023 FY | 89.62 Million SEK | -44.64% |
| 2022 Q3 | 54.88 Million SEK | 53.88% |
| 2022 FY | 161.9 Million SEK | 50.0% |
| 2022 Q4 | 39.1 Million SEK | -28.76% |
| 2022 Q2 | 35.66 Million SEK | 8.03% |
| 2022 Q1 | 33.01 Million SEK | 19.34% |
| 2021 FY | 107.93 Million SEK | 14.31% |
| 2021 Q2 | 27.76 Million SEK | 10.98% |
| 2021 Q3 | 27.47 Million SEK | -1.05% |
| 2021 Q4 | 27.66 Million SEK | 0.69% |
| 2021 Q1 | 25.02 Million SEK | 11.46% |
| 2020 Q1 | 22.15 Million SEK | -20.82% |
| 2020 Q4 | 22.44 Million SEK | 9.02% |
| 2020 Q3 | 20.59 Million SEK | -29.55% |
| 2020 Q2 | 29.23 Million SEK | 31.96% |
| 2020 FY | 94.42 Million SEK | -3.91% |
| 2019 Q4 | 27.97 Million SEK | 58.46% |
| 2019 Q2 | 36.51 Million SEK | 126.61% |
| 2019 Q1 | 16.11 Million SEK | -59.65% |
| 2019 FY | 98.26 Million SEK | 18.69% |
| 2019 Q3 | 17.65 Million SEK | -51.66% |
| 2018 Q2 | 17.4 Million SEK | 139.63% |
| 2018 FY | 82.78 Million SEK | 54.11% |
| 2018 Q4 | 39.93 Million SEK | 119.63% |
| 2018 Q3 | 18.18 Million SEK | 4.48% |
| 2018 Q1 | 7.26 Million SEK | -77.47% |
| 2017 Q1 | 24.44 Million SEK | 124.26% |
| 2017 FY | 53.71 Million SEK | 19.98% |
| 2017 Q2 | 13.85 Million SEK | -43.32% |
| 2017 Q4 | 32.23 Million SEK | 77.06% |
| 2017 Q3 | 18.2 Million SEK | 31.44% |
| 2016 Q1 | 11.24 Million SEK | 0.0% |
| 2016 FY | 44.77 Million SEK | 20.12% |
| 2016 Q4 | 10.89 Million SEK | -4.21% |
| 2016 Q3 | 11.37 Million SEK | -7.08% |
| 2016 Q2 | 12.24 Million SEK | 8.84% |
| 2015 FY | 37.27 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -3.275% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -1722.46% |
| SQZ Biotechnologies Company | 85.61 Million USD | -4.681% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -203.275% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -140.573% |
| Mesoblast Limited | 5.9 Million USD | -1418.587% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -5867.578% |
| Genus plc | 147.7 Million USD | 39.318% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -920.898% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -6580.879% |
| Marizyme, Inc. | 19.23 Million USD | -365.841% |
| ContraFect Corporation | 56.88 Million USD | -57.547% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -974.793% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -1932.97% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -5960.989% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -2973.381% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -3112.026% |
| MultiCell Technologies, Inc. | 567.42 USD | -15795430.647% |
| Accustem Sciences Inc. | 3.74 Million USD | -2292.338% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -4.284% |
| EV Biologics, Inc. | 531.96 Thousand USD | -16748.384% |
| Q BioMed Inc. | 3.43 Million USD | -2507.992% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -262.642% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -22906.885% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -3311.085% |
| Biomind Labs Inc. | 994.18 Thousand USD | -8915.15% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 60.253% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -1234.129% |
| Skye Bioscience, Inc. | 13.54 Million USD | -561.573% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -4274.812% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 358608.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -1677.593% |
| IMV Inc. | 37.7 Million USD | -137.679% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -459.811% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -4784.052% |
| GB Sciences, Inc. | 1.42 Million USD | -6209.499% |
| Alpha Cognition Inc. | 9.7 Million USD | -823.456% |
| HST Global, Inc. | 140.9 Thousand USD | -63507.202% |
| CSL Limited | 3.44 Billion USD | 97.401% |
| Halberd Corporation | 74.84 Thousand USD | -119654.95% |
| Enzolytics Inc. | 2.17 Million USD | -4012.26% |
| Resverlogix Corp. | 12.71 Million USD | -605.058% |
| Affymax, Inc. | 39.38 Million USD | -127.561% |
| SYBLEU INC | 160.87 Thousand USD | -55611.853% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -2355.059% |
| argenx SE | 1.53 Billion USD | 94.156% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -56.036% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -8484.962% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -5574.912% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -2532.234% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1126.043% |
| Zenith Capital Corp. | 8.94 Million USD | -902.203% |
| Genscript Biotech Corporation | 825.34 Million USD | 89.141% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -514376.781% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -3550.323% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -52157.899% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 9.769% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -4993.375% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -4444.901% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -4707.361% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -724.763% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -4565.871% |
| BioStem Technologies, Inc. | 22.97 Million USD | -290.11% |
| ONE Bio Corp. | 6.44 Million USD | -1290.883% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -49285.349% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -6611.466% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -7867.482% |
| Agentix Corp. | 1.37 Million USD | -6433.742% |
| LadRx Corporation | 3.81 Million USD | -2251.309% |
| Cell Source, Inc. | 4.32 Million USD | -1972.135% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -21471.969% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -9605.038% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -9605.038% |
| NovAccess Global Inc. | 2.46 Million USD | -3533.388% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -3626.797% |
| Itoco Inc. | 919.14 Thousand USD | -9651.149% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -2014.635% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -7909.562% |
| Kadimastem Ltd | 2.41 Million USD | -3618.79% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -34144.592% |
| CytoDyn Inc. | 18.05 Million USD | -396.328% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -356000.759% |
| Mobile Lads Corp. | 554.54 Thousand USD | -16062.23% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -40625.107% |
| Qrons Inc. | 643.67 Thousand USD | -13824.22% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -6212.685% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -3919.366% |
| Rebus Holdings, Inc. | 664 Thousand USD | -13398.042% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -4834.538% |
| International Stem Cell Corporation | 5.27 Million USD | -1600.379% |
| Bioxytran, Inc. | 3.82 Million USD | -2246.166% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -170157.589% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -440479.069% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -147.138% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -5439.37% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -12080.312% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -2780.971% |
| Neutra Corp. | 243.82 Thousand USD | -36659.344% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -413.416% |
| PureTech Health plc | 144.59 Million USD | 38.016% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -337.421% |
| IXICO plc | 4.7 Million USD | -1804.122% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -918.836% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 23.882% |
| CSL Limited | 3.89 Billion USD | 97.698% |
| Cellectis S.A. | 97.32 Million USD | 7.905% |